Exenatide
Exendin-4 (nasal research spray) — Byetta/Bydureon are the injectable forms
Exenatide (Exendin-4 (nasal research spray) — Byetta/Bydureon are the injectable forms) is a metabolic & fat loss research compound. GLP-1 agonist derived from exendin-4 (Gila monster) — the original incretin drug; resists DPP-4 breakdown.
Exenatide quick facts
| Reported research dose | 50mcg-200mcg (1-4 sprays · 50mcg per spray) — titrate to individual response |
| Route | Nasal |
| Frequency | As needed · As needed |
| Half-life | ~2.4 hrs |
| Forms | Nasal |
| Evidence level | FDA-approved as a subcutaneous injectable; the nasal spray format is a research preparation and is NOT the approved product |
Sold as a finished nasal spray, so there is nothing to reconstitute and no needle. Dose to response rather than a fixed schedule. Nasal delivery of a peptide this size has not been characterized for how much actually crosses — treat the per-spray figure as what is in the bottle, not what is absorbed.
How Exenatide works
GLP-1 agonist derived from exendin-4 (Gila monster) — the original incretin drug; resists DPP-4 breakdown.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Where to get Exenatide
Buy Exenatide at Disguised Alpha →The evidence for Exenatide
Graded by what exists behind each claim.
✅ Clinically validated
- The first GLP-1 agonist ever approved — Byetta in 2005, then Bydureon weekly. Approval rested on the AMIGO trials showing HbA1c reduction and modest weight loss in type 2 diabetes.
- EXSCEL (14,752 patients) tested cardiovascular outcomes and missed superiority — it showed non-inferiority but not the clear benefit liraglutide and semaglutide demonstrated. Worth reading precisely: the safety signal was clean, the benefit was not proven, and adherence in the trial was poor.
📊 Correlative data
- Twenty years of prescribing. The consistently reported problems are nausea and, with the extended-release form, injection-site nodules that can persist for months — a formulation issue rather than a drug one.
🧪 Theoretical / extrapolated
- A synthetic version of exendin-4, isolated from Gila monster venom — it shares only about 53% homology with human GLP-1, which is why it resists DPP-4 degradation naturally.
- That low homology is also why it is the most immunogenic of the class: anti-drug antibodies develop in a meaningful fraction of users and can blunt the response. The later agonists were engineered closer to the human sequence specifically to avoid this.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Exenatide actually does
Exenatide is lizard venom, and the venom is the reason it works. Eng 1992 isolated a 39-amino-acid peptide from the venom of Heloderma suspectum, the Gila monster, using an assay for peptides carrying an amino-terminal histidine. They called it exendin-4. It differs from exendin-3 by two substitutions — Gly2-Glu3 in place of Ser2-Asp3 — and is otherwise identical. In dispersed guinea pig pancreatic acini it produced a monophasic rise in cAMP beginning at 100 pM and plateauing at 10 nM, progressively inhibited by the antagonist exendin-(9-39) amide. Those are the numbers that define the pharmacology, and they were published in 1992.
What it does at the receptor. The label's own wording: exenatide “is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying”, and “the amino acid sequence of exenatide partially overlaps that of human GLP-1” U.S. Food and Drug Administration 2025. Partially is doing real work in that sentence: this is not a GLP-1 analog in the sense that semaglutide is a modified human GLP-1. It is a different animal's peptide that happens to fit the human receptor.
The single most important structural fact, and it is one amino acid. Human GLP-1 is destroyed within minutes by dipeptidyl peptidase-4, which cleaves after the residue at position 2 — an alanine. Exendin-4 has glycine at position 2 Eng 1992. Glycine has no side chain, DPP-4 does not cleave it, and a peptide that would otherwise last two minutes lasts hours. Every GLP-1 drug in existence solves this problem somehow; exenatide is the one where evolution solved it first, in a venom, for an entirely unrelated reason.
Glucose-dependence is what separates this class from insulin. The receptor amplifies glucose-stimulated insulin secretion rather than triggering secretion directly, so when glucose is low the beta-cell has nothing to amplify. That is why the label's hypoglycemia numbers are unremarkable on their own and dramatic in combination with a sulfonylurea, which is not glucose-dependent: 14.4% at 5 mcg twice daily and 35.7% at 10 mcg twice daily when a sulfonylurea is on board U.S. Food and Drug Administration 2025.
And a note this site's card makes necessary. The card lists a nasal route at 50–200 mcg per administration. The receptor pharmacology above says nothing about routes; what it says is that a 39-residue peptide has to reach the circulation intact to reach a pancreatic beta-cell. Nasal mucosa is a route with a real absorption literature for small peptides, and there is no published bioavailability figure for intranasal exenatide to put a number on. That gap is the subject of the pharmacokinetics section and it is the most consequential unknown on this page.
Cell, rodent, human — and where it stops
Step one, isolated pancreatic acini. Eng 1992: natural and synthetic exendin-4, cAMP from 100 pM, plateau at 10 nM, blocked by exendin-(9-39). Unlike exendin-3, exendin-4 did not stimulate amylase release and did not displace radiolabelled VIP, which is how the authors concluded it acts only at the exendin receptor. Clean, specific, and thirty-four years old.
Step two, the approved human program. Byetta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, at 5 mcg subcutaneously twice daily within the 60-minute window before the morning and evening meals, increasing to 10 mcg twice daily after a month U.S. Food and Drug Administration 2025. Not a weight-loss indication. Not once weekly. Not nasal. Those distinctions matter because the safety database attaches to the product that was studied.
Step three, the cardiovascular outcome trial, and it is a null result reported honestly. EXSCEL Holman 2017 randomized 14,752 patients — 10,782 (73.1%) with existing cardiovascular disease — to once-weekly extended-release exenatide 2 mg or placebo, followed for a median of 3.2 years. The primary composite of cardiovascular death, non-fatal MI or non-fatal stroke occurred in 839 of 7,356 (11.4%; 3.7 per 100 person-years) on exenatide and 905 of 7,396 (12.2%; 4.0 per 100 person-years) on placebo: hazard ratio 0.91, 95% CI 0.83 to 1.00. Non-inferior for safety at P < 0.001; not superior for efficacy at P = 0.06. The upper confidence bound touched exactly 1.00 and the trial missed by four hundredths of a p-value. Rates of pancreatitis, pancreatic cancer, medullary thyroid carcinoma and serious adverse events did not differ.
Step four, the pooled physiology. Robinson 2013 meta-analyzed 32 trials of exenatide and liraglutide and found GLP-1 agonists increased heart rate by 1.86 bpm (95% CI 0.85 to 2.87) versus placebo and by 1.90 bpm versus active control, lowered systolic blood pressure by 1.79 mmHg (95% CI 0.64 to 2.94), failed to move diastolic pressure significantly, and reduced body weight by 1.22 kg versus placebo and 3.31 kg versus active control. Note the weight number: against placebo, roughly a kilogram. This is the honest size of the effect for this molecule, and it is a fraction of what the current generation of incretin drugs produces.
The obstacle, and on this page it is a route rather than a species. Everything above — every milligram, every hazard ratio, every adverse-event percentage — comes from subcutaneous exenatide at 5 to 10 mcg twice daily or 2 mg once weekly. This site's card describes a nasal spray at 50 mcg per spray, 1 to 4 sprays. There is no approved nasal exenatide, no published intranasal pharmacokinetic study, and therefore no way to convert a nasal dose into a systemic exposure that any of the above applies to. If nasal bioavailability were 10%, four sprays would deliver about 20 mcg systemically — twice the maximum labeled subcutaneous dose. If it were 1%, four sprays would deliver 2 mcg, less than half the starting dose. Nobody can say which, and the two answers are not close.
Exenatide pharmacokinetics — how much of it actually gets in
The approved route is subcutaneous and the numbers are all published. Median Tmax 2.1 hours; mean apparent volume of distribution 28.3 L; apparent clearance 9.1 L/hour; terminal half-life 2.4 hours, with concentrations measurable for approximately 10 hours after a dose U.S. Food and Drug Administration 2025. This site's card gives about 2.4 hours, which matches the label exactly.
What clears it, and why the kidney is the organ that matters. Exenatide is “predominantly eliminated by glomerular filtration with subsequent proteolytic degradation” U.S. Food and Drug Administration 2025. That is unusual and it is consequential: this is not a hepatic drug, there is no cytochrome P450 step to interact with, and the entire elimination pathway is a filter. The label accordingly states it is not recommended in severe renal impairment (creatinine clearance below 30 mL/min) and carries post-marketing reports of acute kidney injury, in some cases requiring hemodialysis. A 4,186 Da peptide filtered at the glomerulus and then chewed up in the proximal tubule is a drug whose exposure rises as renal function falls, and whose adverse effect is on the organ doing the clearing.
The apparent clearance number is worth doing arithmetic with. 9.1 L/hour against a volume of distribution of 28.3 L gives an elimination rate constant of about 0.32 per hour, which is a half-life of about 2.2 hours — consistent with the label's 2.4. The two numbers are internally coherent, which is more than can be said for most half-lives quoted in this catalog.
The immunogenicity data is the part nobody reads and it is a pharmacokinetic problem. The label reports that 360 patients (38%) had low-titre antibodies (below 625) and 59 patients (6%) had higher-titre antibodies (625 or above) at 30 weeks; of those, 32 patients (3% overall) had an attenuated glycemic response U.S. Food and Drug Administration 2025. A foreign 39-residue peptide from a reptile provokes antibodies in more than a third of people, and in a small minority those antibodies neutralize the drug. Someone whose response fades after six months has a documented mechanism for it.
And the nasal question, stated as the arithmetic it is. There is no published intranasal exenatide bioavailability figure, so the honest statement is a bound rather than a value: a peptide of this size crossing nasal epithelium without a permeation enhancer is generally in the low single-digit percent, and a route that delivered the labeled 10 mcg systemically from a 50 mcg spray would imply 20% — higher than most nasal peptides achieve. The uncertainty spans more than an order of magnitude, and every dose comparison on this page depends on which end of it is true. This is the number somebody should measure, and until they do, the subcutaneous label is the only exposure anyone can reason from.
What would have to be true, and how you would know it was not
Five predictions with a marker, a direction and a window. The second is the one that cuts against the drug and the fifth is the falsification test for the route this site sells.
1. Fasting glucose and HbA1c should fall. This is the approved endpoint and the mechanism is glucose-dependent insulin secretion plus glucagon suppression U.S. Food and Drug Administration 2025. Draw Fasting Glucose and Hemoglobin A1c (HbA1c) at baseline and at 12 weeks — twelve rather than four, because HbA1c reflects roughly three months of red-cell exposure and a shorter window measures the assay's inertia rather than the drug.
2. The prediction that cuts against it: resting heart rate should rise. Robinson 2013 pooled 32 trials and found +1.86 bpm versus placebo (95% CI 0.85 to 2.87), an effect the authors note was more evident for long-acting preparations than for twice-daily exenatide. That is small on average and it is not small in everyone, and the mechanism is unresolved — the meta-analysis says so explicitly. Measure resting heart rate seated, same time of day, weekly. Somebody stacking this with a beta-agonist, or with anything else that raises rate, is stacking two effects nobody has studied together.
3. Weight should fall by about a kilogram against placebo, not by ten. Robinson 2013 gives −1.22 kg versus placebo across the pooled trials. Anyone expecting a modern incretin's weight response from this molecule is expecting a different drug's number. Weigh at the same time of day, fasted, weekly for 12 weeks.
4. Lipase and amylase are not screening tests, and this is worth stating. The label carries acute pancreatitis — including fatal and non-fatal hemorrhagic or necrotizing pancreatitis — as a warning U.S. Food and Drug Administration 2025, and asymptomatic enzyme elevations are common enough on this class to generate anxiety without generating information. The read-out for pancreatitis is severe, persistent abdominal pain radiating to the back, with or without vomiting, and the response is to stop and be assessed, not to order an enzyme.
5. The route falsification test, and it costs nothing. If the nasal preparation is delivering meaningful systemic exenatide, then the two most reliable pharmacodynamic signatures of this drug should appear: delayed gastric emptying — felt as early fullness and reduced appetite within the first hour — and nausea, which the label puts at 44% versus 18% on placebo in the 30-week combination trial U.S. Food and Drug Administration 2025. Absence of both, consistently, across several doses, is direct evidence that the nasal route is not delivering the drug. That is a genuinely falsifiable claim about a product this site lists, and nobody has run it.
What nobody has tested yet
Nobody has published the intranasal bioavailability of exenatide. This is the central unknown of the page and it is answerable with a small crossover study: the same volunteers, a labeled subcutaneous dose on one day and a nasal dose on another, plasma exenatide by immunoassay over 10 hours, and the ratio of the AUCs. Twelve people, two visits. Until that exists, every dose conversion between the nasal preparation this site lists and the labeled product is guesswork, and the guess spans more than tenfold in either direction.
Nobody has tested whether the nasal route reaches the brain differently. The nose is the one peripheral site with a proposed direct anatomical route to the CNS along the olfactory and trigeminal nerves, and GLP-1 receptors are expressed in the hypothalamus and brainstem where appetite is regulated. If intranasal delivery favors central over systemic exposure, the appetite effect and the glycemic effect would separate — which would be genuinely novel and is exactly the kind of hypothesis this space exists to test. No study has compared central and peripheral read-outs by route for this peptide.
Nobody has explained the heart-rate rise. Robinson 2013's own conclusion is that “mechanisms underlying the rise in heart rate require further investigation”. Thirteen years later there is still no settled answer for a reproducible 1.9 bpm effect across 32 trials, and this class is now taken by millions of people.
Nobody has re-run EXSCEL's near-miss. A hazard ratio of 0.91 with an upper bound of exactly 1.00 and P = 0.06 Holman 2017 is the most tantalizing result in this drug's file: it is either a real, modest cardiovascular benefit that the trial was slightly underpowered to prove, or it is noise. No confirmatory trial of exenatide has been run to settle it, and the field moved on to newer molecules instead.
Exenatide — its own safety story, not its class's
The gastrointestinal numbers are the ones people actually meet. In the 30-week trial in combination with metformin and a sulfonylurea (N = 963 on Byetta), the label reports nausea 44% versus 18% on placebo, vomiting 13% versus 4%, diarrhea 13% versus 6%, feeling jittery 9% versus 4%, dizziness 9% versus 6% and headache 9% versus 6% U.S. Food and Drug Administration 2025. In monotherapy over 24 weeks the same numbers are far smaller — nausea 8% versus 0%, vomiting 4% versus 0%. The difference between those two tables is the co-medication, and it is the clearest illustration on the page that this drug's tolerability is a property of the stack rather than of the molecule.
The hypoglycemia risk is entirely about what it is taken with. With a sulfonylurea: 14.4% at 5 mcg twice daily and 35.7% at 10 mcg twice daily U.S. Food and Drug Administration 2025. The mechanism is that exenatide's insulin release is glucose-dependent and a sulfonylurea's is not, so the two are not additive risks — the sulfonylurea supplies the floor-piercing component. Anyone combining this with insulin, a sulfonylurea, prolonged fasting or hard training should treat those percentages as the relevant number rather than the monotherapy ones.
Pancreatitis and the kidney are the two organ warnings. The label carries acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, without an incidence figure, and post-marketing reports of acute kidney injury, in some cases requiring hemodialysis, with the drug not recommended below a creatinine clearance of 30 mL/min U.S. Food and Drug Administration 2025. Against that, EXSCEL — 14,752 patients over a median 3.2 years — found no significant difference in acute pancreatitis, pancreatic cancer or medullary thyroid carcinoma between exenatide and placebo Holman 2017. Both statements are true and both belong on the page: the warning describes what has been reported, the trial describes what a large randomized comparison could detect.
The rodent thyroid finding, in its own units. Carcinogenicity studies in rats produced benign thyroid C-cell adenomas at all exenatide doses, at exposures 5 to 130 times human exposure U.S. Food and Drug Administration 2025. Exenatide carries no boxed warning for this — unlike the long-acting GLP-1 agonists — and EXSCEL found no medullary thyroid carcinoma signal in nearly fifteen thousand people Holman 2017. Worth knowing, worth keeping in proportion.
Three warnings that are easy to miss and matter to this readership. Acute gallbladder disease at 1.9% versus 1.4% on placebo; drug-induced immune-mediated thrombocytopenia; and pulmonary aspiration during anesthesia or deep sedation, which follows directly from delayed gastric emptying and is the reason anesthetists now ask about this class before any procedure U.S. Food and Drug Administration 2025. Anyone on this drug going for surgery, dentistry under sedation or an endoscopy needs to say so.
And the risk that belongs to this site's version rather than to the drug. The approved product is a subcutaneous pen at 5 or 10 mcg. The preparation described on this card is nasal at 50 mcg per spray, with no approved product, no published route pharmacokinetics, and therefore no validated relationship between what is administered and what arrives. Every percentage in this section attaches to a known systemic exposure; none of them can be assumed to transfer to an exposure nobody has measured — in either direction. The label also warns never to share pens between patients, and the analogous hazard for a shared nasal device is the same one.
Sources read for this page
- U.S. Food and Drug Administration. BYETTA (exenatide) injection, for subcutaneous use - full prescribing information (NDA 021773).. FDA approved labeling, revision 2025
- Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.. J Biol Chem 1992 · PMID 1313797
- Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Ohman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.. N Engl J Med 2017 · PMID 28910237
- Robinson LE, Holt TA, Rees K. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.. BMJ Open 2013 · PMID 23355666
Exenatide — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centers. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognized signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumor signal exists in rodents and has not been demonstrated in humans; it is why the labeled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fiber and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Exenatide — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Exenatide moves on your bloodwork
Expected direction, not a measured one.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Exenatide in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Exenatide
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Baseline |
| Lipase | Pancreatitis monitoring |
| Comprehensive Metabolic Panel (CMP) | Kidney especially — exenatide is renally cleared |
| Cystatin C with eGFR | The kidney marker that isn't distorted by muscle mass |
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel covers these in one order — 11 markers, $148.05 with the discount applied.
Check results you already have → · All 103 markers A–Z
Exenatide — frequently asked questions
What is Exenatide?
Exenatide (Exendin-4 (nasal research spray) — Byetta/Bydureon are the injectable forms) is a metabolic & fat loss research compound. GLP-1 agonist derived from exendin-4 (Gila monster) — the original incretin drug; resists DPP-4 breakdown.
Is the full Exenatide protocol on this page?
The reported research dose is on this page, along with how Exenatide works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Exenatide?
Exenatide has an approximate half-life of ~2.4 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Exenatide?
Current evidence level: FDA-approved as a subcutaneous injectable; the nasal spray format is a research preparation and is NOT the approved product. Exenatide is offered for research purposes only and is not an approved medicine.
What Exenatide is used for
Exenatide appears under 2 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.